Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has been given a consensus rating of “Moderate Buy” by the seventeen brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $685.3077.

Several equities analysts recently weighed in on the stock. B. Riley Financial increased their price target on shares of Madrigal Pharmaceuticals from $560.00 to $670.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Truist Financial lifted their price objective on shares of Madrigal Pharmaceuticals from $580.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, November 19th. Wolfe Research set a $579.00 target price on shares of Madrigal Pharmaceuticals in a research note on Tuesday, January 6th. Piper Sandler increased their target price on shares of Madrigal Pharmaceuticals from $540.00 to $900.00 and gave the company an “overweight” rating in a research report on Friday, December 19th. Finally, Barclays initiated coverage on shares of Madrigal Pharmaceuticals in a research note on Tuesday, January 27th. They set an “overweight” rating and a $964.00 price target for the company.

Madrigal Pharmaceuticals Stock Performance

Shares of Madrigal Pharmaceuticals stock opened at $432.83 on Friday. The business’s fifty day simple moving average is $492.64 and its 200 day simple moving average is $487.47. The company has a current ratio of 4.01, a quick ratio of 3.77 and a debt-to-equity ratio of 0.56. Madrigal Pharmaceuticals has a 12 month low of $265.00 and a 12 month high of $615.00. The firm has a market capitalization of $9.93 billion, a P/E ratio of -33.63 and a beta of -0.97.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($2.57) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($2.61). The business had revenue of $321.08 million for the quarter, compared to analysts’ expectations of $310.36 million. Madrigal Pharmaceuticals had a negative net margin of 30.08% and a negative return on equity of 43.76%. The company’s revenue for the quarter was up 210.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($2.71) earnings per share. As a group, analysts anticipate that Madrigal Pharmaceuticals will post -23.47 EPS for the current year.

Insider Buying and Selling at Madrigal Pharmaceuticals

In other news, CEO William John Sibold sold 1,663 shares of the company’s stock in a transaction on Friday, March 6th. The stock was sold at an average price of $431.94, for a total transaction of $718,316.22. Following the transaction, the chief executive officer owned 161,829 shares of the company’s stock, valued at $69,900,418.26. This represents a 1.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Mardi Dier sold 1,982 shares of the company’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $430.87, for a total value of $853,984.34. Following the transaction, the chief financial officer directly owned 12,490 shares in the company, valued at $5,381,566.30. This represents a 13.70% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 99,062 shares of company stock valued at $52,317,727 in the last quarter. Insiders own 21.50% of the company’s stock.

Institutional Investors Weigh In On Madrigal Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. AlphaQuest LLC lifted its holdings in Madrigal Pharmaceuticals by 412.5% during the second quarter. AlphaQuest LLC now owns 82 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 66 shares during the last quarter. Flagship Harbor Advisors LLC purchased a new position in shares of Madrigal Pharmaceuticals in the fourth quarter worth about $29,000. Mather Group LLC. purchased a new position in shares of Madrigal Pharmaceuticals in the third quarter worth about $33,000. Global Retirement Partners LLC raised its position in shares of Madrigal Pharmaceuticals by 221.7% in the third quarter. Global Retirement Partners LLC now owns 74 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 51 shares during the period. Finally, First Horizon Corp bought a new stake in shares of Madrigal Pharmaceuticals in the third quarter valued at approximately $34,000. Hedge funds and other institutional investors own 98.50% of the company’s stock.

Key Headlines Impacting Madrigal Pharmaceuticals

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Company granted inducement equity awards to 20 new non‑executive hires under Nasdaq Rule 5635(c)(4), which can help recruit talent and support execution of the pipeline programs. Madrigal Announces Grants of Inducement Awards
• Neutral Sentiment: All insider trades were formally reported via SEC Form 4 filings (standard disclosure), so the transactions are public and fully documented. Example SEC Form 4 Filing
• Negative Sentiment: CEO William John Sibold sold 1,663 shares (~$718k); his holdings fell ~1.02% after the sale. CEO Form 4
• Negative Sentiment: CFO Mardi Dier sold 1,982 shares (~$854k); this represented a ~13.7% reduction in her ownership. Large percentage cuts by the CFO can be read as a stronger negative signal. CFO Form 4
• Negative Sentiment: General Counsel Shannon T. Kelley sold 360 shares (~$155k), a ~2.88% position reduction. GC Form 4
• Negative Sentiment: Director Rebecca Taub sold 491 shares (~$212k); she still retains a large stake (~452k shares) but reduced ownership slightly. Director Form 4
• Negative Sentiment: Insider Carole Huntsman sold 419 shares (~$181k), a ~3.20% decrease in her holding. Insider Form 4

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.